PCSK9 inhibitors are a class of monoclonal antibodies that reduce low-density lipoprotein cholesterol (LDL-C) levels by preventing the degradation of LDL receptors on liver cells, enhancing cholesterol clearance from the bloodstream. They are clinically important for managing hypercholesterolaemia, particularly in patients who are statin-intolerant or have familial hypercholesterolaemia, to reduce cardiovascular risk. A key consideration is their high cost and the need for subcutaneous administration, which may affect patient adherence.